WorldCat Linked Data Explorer

Turtle N-Triple JSON-LD RDF/XML HTML Contact Us Home

http://worldcat.org/entity/work/id/50020134

Market size in innovation : theory and evidence from the pharmaceutical industry

This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1 percent increase in the potential market size for a drug category leads to a 4 to 6 percent increase in the number of new drugs in that category. This response comes from both the entry of generic drugs and new non-generic drugs, and is generally robust to controlling for a variety of non-profit factors, pre-existing trends, and changes in health care coverage. Keywords: Economic Growth, Entry, Innovation, Pharmaceuticals, Profit Incentives. JEL Classifications: O31, O33, L65.

Open All Close All

type

about

author

contributor

creator

description

http://schema.org/description

  • "This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1 percent increase in the potential market size for a drug category leads to a 4 to 6 percent increase in the number of new drugs in that category. This response comes from both the entry of generic drugs and new non-generic drugs, and is generally robust to controlling for a variety of non-profit factors, pre-existing trends, and changes in health care coverage. Keywords: Economic Growth, Entry, Innovation, Pharmaceuticals, Profit Incentives. JEL Classifications: O31, O33, L65."@en
  • ""This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1 percent increase in the potential market size for a drug category leads to a 4 to 6 percent increase in the number of new drugs in that category. This response comes from both the entry of generic drugs and new non-generic drugs, and is generally robust to controlling for a variety of non-profit factors, pre-existing trends"--NBER website."@en

name

http://schema.org/name

  • "Market size in innovation : theory and evidence from the pharmaceutical industry"
  • "Market size in innovation : theory and evidence from the pharmaceutical industry"@en
  • "Market Size in Innovation Theory and Evidence From the Pharmaceutical Industry"@en
  • "Market Size in Innovation : Theory and Evidence From the Pharmaceutical Industry"
  • "Market size in innovation theory and evidence from the pharmaceutical industry"@en
  • "Market size in innovation theory and evidence from the pharmaceutical industry"
  • "Market size in innovation: theory and evidence from the pharmaceutical industry"

workExample